lymphocyte immune globulin, anti-thymocyte globulin
lymphocyte immune globulin, anti-thymocyte globulin: 11 clinical trials tracked.
lymphocyte immune globulin, anti-thymocyte globulin evidence translation
What we can confirm
11 tracked trials
What it means
What to watch
Prepared research question
What is verified about lymphocyte immune globulin, anti-thymocyte globulin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (11)showing 10 most recent
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Primary endpoint: To assess the safety of combining CD19-CAR(Mem) T cells after TCRαβ+/CD19 depleted haploidentical donor transplantation for pediatric patients with relapsed/refractory CD19+ B-cell malignancies.
A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients
Primary endpoint: Composite efficacy failure rate (BPAR, graft loss, and death) by 1 year post kidney transplantation
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
Primary endpoint: Stimulated C-peptide AUC
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Primary endpoint: Number of participants experiencing grade 3-4 GVHD and/or transplant related mortality (TRM).
A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Severe Aplastic Anemia Patients With COH-MC-17: A Non-Myeloablative/ Reduced-Intensity, Conditioning Regimen and CD4+ T-Cell-Depleted Haploidentical Hematopoietic Transplant
Primary endpoint: Incidence of adverse events
A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML
Primary endpoint: Safety of patients being administered donor-derived ML NK cells following TCR alpha beta depleted haploidentical cell transplant
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Primary endpoint: The primary endpoint of this trial is time from randomization to treatment failure or death from any cause.
Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia
Primary endpoint: Engraftment
Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease
Primary endpoint: Change in mucosal healing
A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin® 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant Recipients
Primary endpoint: Percentage of Participants With Composite Efficacy Failure at 12 Months